Media Releases - Genmab A/S

Skip to main navigation

Global

Japan
USA

Healthcare Professionals
Patients & Care Partners
Partnerships
Contact

About
Back

Transforming the treatment of cancer and other serious diseases

About Genmab
FEATURED

A history of accomplishments rooted in science
Antibody Science
Back

Pioneering technologies that create novel antibody therapeutics to treat cancer and other serious diseases.

Antibody Science Overview
FEATURED

Science that can transform lives
Our Impact
Back

Discover how Genmab makes a positive impact for patients, communities and employees

Our Impact
FEATURED

Incorporating the patient perspective
Investors
Back

Corporate and financial resources for Genmab investors, potential shareholders and analysts

Investor Relations
FEATURED

Genmab at a Glance
News & Insights
Back

Find press releases, articles and access media from Genmab

Latest Updates
FEATURED

Genmab Hosts Plenary and Life Science Fair on AI’s Role in the Future of Healthcare and Labs
Careers

Healthcare Professionals
Patients & Care Partners
Partnerships
Contact

Genmab regional sites

Japan
USA

Genmab Appoints Margarida Duarte as General Manager, Europe and Emerging Markets

Read more about Genmab Appoints Margarida Duarte as General Manager, Europe and Emerging Markets

Genmab to Participate in Upcoming Investor Conferences

Read more about Genmab to Participate in Upcoming Investor Conferences

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Read more about Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence

Read more about Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence

Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference

Read more about Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference

Genmab to Hold 2025 R&D Update and ASH Data Review Meeting

Read more about Genmab to Hold 2025 R&D Update and ASH Data Review Meeting

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

Read more about Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

Read more about Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

Read more about Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes

Read more about Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes

Pagination

Page 1
Next page

Subscribe to Media Releases

Transforming lives with pioneering antibody science

Quick Links

News
Medicines
Pipeline
Stories

Explore

About
Antibody Science
Impact
Investors
News & Insights
Careers

Resources

Healthcare Professionals
Patients & Care Partners

Genmab Websites

Japan Opens in a new tab
USA Opens in a new tab

Get in touch

Contact us

Follow Genmab

Accessibility Policy
Cookie Policy
Your Cookie Preferences
Disclaimer
Privacy Policy
Social Media Terms of Use

©2026 Genmab A/S

You are now leaving Genmab.com to go to our collaborator’s website.

If you continue, we encourage you to read the website’s privacy and cookie policy.

Continue